Abstract PS2-06-30: Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with HER2-negative recurrent high-risk early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness)
View Full Paper
Ask AI
Bookmark
Share
Key Points
To evaluate the real-world uptake of gBRCA testing among patients with HER2-negative recurrent high-risk early breast cancer in Japan.
Cross-sectional multicenter study conducted in Japan from January to December 2023.
Enrolled newly diagnosed patients with invasive HER2-negative breast cancer undergoing curative surgery.
Collected patient-level and institutional data regarding gBRCA testing and treatment outcomes.
63.2% of enrolled patients underwent gBRCA testing.
66% of untested patients were not informed about the testing option, primarily due to physician oversight.
9.6% of tested patients had pathogenic variants, with 32 receiving olaparib treatment.
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
A multicenter study assesses gBRCA testing uptake in HER2-negative early breast cancer, highlighting significant gaps in awareness and access.